CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 48 enrolled
Drug / intervention
avelumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05012865
NCT05012865N/ACompleted
CompareCT.gov

Retrospective, Multicenter, Observational Study to Evaluate Current Treatment Outcomes in Japanese Patients With Metastatic Renal Cell Carcinoma Treated With Avelumab Plus Axitinib as a First-line Therapy

Pfizer·observational·Posted Aug 19, 2021·Updated Dec 6, 2023

In Brief

An observational study evaluating avelumab and axitinib for Renal Cell Carcinoma. Completed, enrolled 48 participants across 12 sites.

Detailed Summary

This study is a multicenter, non-interventional, retrospective, medical chart review of patients with metastatic renal cell cancer(mRCC) treated with avelumab plus axitinib as a first-line therapy in Japan between 20 December 2019 and 20 December 2020. All decisions regarding clinical management and treatment of the participating patients were made by the investigator as part of standard care in real-world clinical setting and were not contingent upon the patient's participation in the study. Data will be collected if available per study site.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedAug 19, 2021
Enrollment StartSep 14, 2021
Primary CompletionJan 31, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.9 years ago

Interventions

avelumabdrug

as provided in real world practice

axitinibdrug

as provided in real world practice